首页> 外文期刊>Critical care : >Plasma suPAR levels are associated with mortality, admission time, and Charlson Comorbidity Index in the acutely admitted medical patient: a prospective observational study
【24h】

Plasma suPAR levels are associated with mortality, admission time, and Charlson Comorbidity Index in the acutely admitted medical patient: a prospective observational study

机译:急性入院患者的血浆suPAR水平与死亡率,入院时间和Charlson合并症指数相关:一项前瞻性观察研究

获取原文
           

摘要

IntroductionSoluble urokinase plasminogen activator receptor (suPAR) is the soluble form of the membrane-bound receptor (uPAR) expressed predominantly on various immune cells. Elevated plasma suPAR concentration is associated with increased mortality in various patient groups, and it is speculated that suPAR is a low-grade inflammation marker reflecting on disease severity. The aim of this prospective observational study was to determine if the plasma concentration of suPAR is associated with admission time, re-admission, disease severity/Charlson Comorbidity Index Score, and mortality.MethodsWe included 543 patients with various diseases from a Danish Acute Medical Unit during a two month period. A triage unit ensured that only medical patients were admitted to the Acute Medical Unit. SuPAR was measured on plasma samples drawn upon admission. Patients were followed-up for three months after inclusion by their unique civil registry number and using Danish registries to determine admission times, readmissions, International Classification of Diseases, 10th Edition (ICD-10) diagnoses, and mortality. Statistical analysis was used to determine suPAR's association with these endpoints.ResultsIncreased suPAR was significantly associated with 90-day mortality (4.87 ng/ml in survivors versus 7.29 ng/ml in non-survivors, P < 0.0001), higher Charlson Score (P < 0.0001), and longer admission time (P < 0.0001), but not with readmissions. The association with mortality remained when adjusting for age, sex, C-reactive protein (CRP), and Charlson Score. Furthermore, among the various Charlson Score disease groups, suPAR was significantly higher in those with diabetes, cancer, cardiovascular disease, and liver disease compared to those without comorbidities.ConclusionsSuPAR is a marker of disease severity, admission time, and risk of mortality in a heterogeneous cohort of patients with a variety of diseases. The independent value of suPAR suggests it could be of value in prognostic algorithms.
机译:简介可溶性尿激酶纤溶酶原激活剂受体(suPAR)是主要在各种免疫细胞上表达的膜结合受体(uPAR)的可溶性形式。血浆suPAR浓度升高与各种患者组的死亡率增加相关,据推测suPAR是反映疾病严重程度的低度炎症标志物。这项前瞻性观察研究的目的是确定suPAR的血浆浓度是否与入院时间,再入院,疾病严重程度/查尔森合并症指数评分和死亡率相关。方法我们纳入了543例来自丹麦急性医疗部门的各种疾病的患者在两个月的时间内。分诊部确保只有医学患者才能进入急性医学科。在入院时抽取的血浆样本中测量SuPAR。在纳入患者后,通过其唯一的民事登记号对患者进行随访三个月,并使用丹麦的登记表确定入院时间,再入院率,《国际疾病分类》,第10版(ICD-10)诊断和死亡率。统计分析用于确定suPAR与这些终点的相关性。结果suPAR升高与90天死亡率显着相关(幸存者为4.87 ng / ml,非幸存者为7.29 ng / ml,P <0.0001),更高的查尔森评分(P < 0.0001)和更长的录取时间(P <0.0001),但不允许重新录取。调整年龄,性别,C反应蛋白(CRP)和查尔森评分后,与死亡率的关系仍然存在。此外,在各种Charlson Score疾病组中,患有糖尿病,癌症,心血管疾病和肝病的suPAR与没有合并症的人相比显着更高。结论SuPAR是疾病严重程度,入院时间和死亡风险的标志。多种疾病患者的异质队列。 suPAR的独立价值表明它可能在预后算法中具有价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号